• Pacira urged shareholders to back its board slate in a proxy fight with activist DOMA Perpetual Capital Management ahead of the June 9 annual meeting.
• The company framed DOMA’s campaign as a push to replace three directors, remove CEO Frank D. Lee, cut costs, halt pipeline investment, and pursue an immediate sale process.
• Pacira highlighted a $300 million share repurchase program launched in April 2025, with $200 million returned so far, and cited a settlement that it said secures EXPAREL exclusivity through 2030.
• It also pointed to operating momentum, including 2025 revenue of $726.4 million and first-quarter EXPAREL revenue of $143.3 million, up 5% year over year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200630PRIMZONEFULLFEED9723176) on May 20, 2026, and is solely responsible for the information contained therein.